Head to Head

ALNY vs OGN: which is the better buy in 2026?

Alnylam Pharmaceuticals

NASDAQ:ALNY

90/100 Compass
True NorthAccumulate$38.5B

RNAi's first profitable platform company is trading near its 52-week low while its pipeline has never been broader or more valuable.

Full ALNY analysis

Organon & Co.

NYSE:OGN

90/100 Compass
True NorthAccumulate$3.5B

A 3.6x forward P/E spinoff drowning in debt that just happens to throw off half a billion in cash, women's health is the call option.

Full OGN analysis

Factor by factor

FactorALNYOGN
Revenue Growth9835
Profitability7742
Valuation2475
Momentum2090
Theme Purity9959
Moat4945
Catalysts9965
Market Position5248

Get head-to-heads like this, free

Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.

Free forever. Unsubscribe anytime. We never share your email.

Frequently asked questions

Is ALNY or OGN the better buy in 2026?

ALNY and OGN are neck and neck at 90/100 on the Compass right now. The better fit depends on which factors matter most to you.

How does Alexandria compare ALNY and OGN?

Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.

Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.